SAINT LAURENT, Quebec, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (the "Company" or "IntelGenx") today reported financial results for the third quarter ended September 30, 2021. All dollar amounts are expressed in U.S. currency, unless otherwise indicated, and results are reported in accordance with United States generally accepted accounting principles except where noted otherwise.

2021 Third Quarter Financial Summary:

  • Revenue was $593,000, compared to $510,000 in the 2020 third quarter.
  • Net comprehensive loss was $2.2 million, compared to $1.6 million in Q3-2020.
  • Adjusted EBITDA loss was $1.4 million, compared to $1.2 million in the 2020 third quarter.

Third Quarter and Recent Developments:

  • Resumed patient screening in the ongoing ‘BUENA’ Montelukast VersaFilm® Phase 2a clinical trial in patients with mild to moderate Alzheimer’s Disease (“AD”) following Health Canada’s issuance of a No Objection Letter in response to the Company’s amended Clinical Trial Application.
  • Graduated to the Toronto Stock Exchange.
  • Announced that its co-development and commercialization partner for Tadalafil oral films for the treatment of erectile dysfunction (ED) and benign prostatic hyperplasia (BPH), Aquestive Therapeutics, Inc. (NASDAQ:AQST), entered into a definitive license and supply agreement with an undisclosed leading men’s health company.
  • Announced that atai Life Sciences AG (“atai”) committed $6.0 million in future financial support to IntelGenx via amendments to the loan facility between the parties.
  • Announced that Exeltis Healthcare S.L., the Company’s commercialization partner in the European Union for RIZAPORT®, a unique treatment for acute migraines, launched the product in Spain.
  • Completed an initial shipment of CBD Filmstrips in support of Heritage Cannabis Holdings Corp.’s (CSE:CANN) Canadian market launch of its “CB4 Control” branded product.
  • Closed a $2.1 million private placement of 8% convertible notes due July 31, 2025, which the Company intends to use to finance its BUENA trial of Montelukast in AD.
  • Increased the size of the Board of Directors from six to eight with the appointments of Srinivas (Srini) G. Rao, M.D., Ph.D. and Frank Stegert.

"The past few months have been a very productive and exciting period for IntelGenx, marked by the achievement of five major milestones,” commented Dr. Horst G. Zerbe, CEO of IntelGenx. “Our graduation to the TSX, Canada’s most senior exchange, came on the heels of our successful transition from a development-stage to a commercial-stage leader in pharmaceutical films as well as our transformational partnership with atai. We were also pleased to resume patient screening in our ongoing ‘BUENA’ Montelukast VersaFilm Phase 2a clinical trial in patients with mild to moderate AD. Having executed on many elements of our growth strategy this quarter, we look forward to continuing to advance our portfolio of innovative film products and product candidates.”

Financial Results:

Total revenues for the three-month period ended September 30, 2021 amounted to $593,000, an increase of $83,000, or 16%, compared to $510,000 for the three-month period ended September 30, 2020. The change is mainly attributable to increases in sales milestone revenues of $320,000, product revenues of $70,000, partially offset by a $308,000 decrease in revenues from licensing agreements.

Operating costs and expenses were $2.2 million for the third quarter of 2021, versus $1.9 million for the corresponding three-month period of 2020. The increase for the three-month period ended September 30, 2021 is mainly attributable to increases of $26,000 in R&D expense, $255,000 in manufacturing expenses, $37,000 in selling, general and administrative expenses, $17,000 in depreciation of tangible assets.

For the third quarter of 2021, the Company had an operating loss of $1.6 million, compared to an operating loss of $1.4 million for the comparable period of 2020.

Net comprehensive loss for the three-month period ended September 30, 2021 was $2.2 million, or $0.01 per basic and diluted share, compared to net comprehensive loss of $1.6 million, or $0.01 per basic and diluted share, for the comparable period of 2020.

As at September 30, 2021, the Company's cash and short-term investments totalled $12.0 million.

Conference Call Details:

IntelGenx will host a conference call to discuss these third quarter 2021 financial results today at 4:30 p.m. ET. The dial-in number for the conference call is (888) 506-0058 (Canada and the United States) and (973) 528-0135 (International), access code 995615. The call will also be webcast live and archived on the Company's website at www.intelgenx.com under "Webcasts" in the Investors section.

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs. IntelGenx’s innovative product pipeline offers significant benefits to patients and physicians for many therapeutic conditions.

IntelGenx's highly skilled team provides comprehensive pharmaceuticals services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, IP and regulatory services. IntelGenx's state-of-the-art manufacturing facility offers full service by providing lab-scale to pilot- and commercial-scale production. For more information, visit www.intelgenx.com.

Forward-Looking Information and Statements
This document may contain forward-looking information about IntelGenx's operating results and business prospects that involve substantial risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, but are not limited to, statements about IntelGenx's plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "could," "would," and similar expressions. All forward looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx's actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the heading "Risk Factors" in IntelGenx's annual report on Form 10-K, filed with the United States Securities and Exchange Commission and available at www.sec.gov, and also filed with Canadian securities regulatory authorities at www.sedar.com. IntelGenx assumes no obligation to update any such forward-looking statements.

Source: IntelGenx Technologies Corp.

For IntelGenx:

Stephen Kilmer
Investor Relations
(647) 872-4849
This email address is being protected from spambots. You need JavaScript enabled to view it.


Andre Godin, CPA, CA
President and CFO
IntelGenx Corp.
(514) 331-7440 ext 203
This email address is being protected from spambots. You need JavaScript enabled to view it.

IntelGenx Technologies Corp.

Consolidated Balance Sheet
(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

 September 30, 2021December 31, 2020
Cash$6,019 $1,205 
Short-term investments 6,013  1,038 
Accounts receivable 1,162  260 
Prepaid expenses 116  162 
Investment tax credits receivable 407  635 
Contract asset -  354 
Security deposits 204  407 
Inventories 68  244 
Total current assets 13,989  4,305 
Leasehold improvements and equipment, net  5,348  5,851 
Security deposits 252  252 
Operating lease right-of-use-asset  1,050  710 
Total assets$20,639 $11,118 
Accounts payable and accrued liabilities 2,304  1,989 
Current portion of long-term debt -  561 
Current portion of operating lease liability 248  141 
Current portion of finance lease liability 35  25 
Deferred revenue 192  166 
Convertible notes -  1,486 
Convertible debentures 5,317  - 
Total current liabilities 8,096  4,368 
Long-term debt 2,500  171 
Convertible notes  3,965  1,505 
Convertible debentures -  5,461 
Operating lease liability  691  482 
Finance lease liability  92  84 
Deferred income tax liability 82  - 
Total liabilities 15,426  12,071 
Subsequent event      
Shareholders' equity      
Capital stock, common shares, $0.00001 par value; 450,000,000 shares authorized; 150,627,761 shares issued and outstanding (2020: 111,429,532 common shares) 1  1 
Additional paid-in capital 61,589  48,453 
Accumulated deficit (55,005)  (48,551) 
Accumulated other comprehensive loss (1,372)  (856) 
Total shareholders’ equity (deficit) 5,213  (953) 
 $20,639 $11,118 

IntelGenx Technologies Corp.

Consolidated Statement of Comprehensive Loss
(Expressed in Thousands of U.S. Dollars ($000’s) Except Share and Per Share Data)

 For the Three-Month Period
For the Nine-Month Period
 Ended September 30,
Ended September 30,
Revenues$593 $510  $1,041 $754 
Total revenues 593  510   1,041  754 
Research and development expense 874  848  1,910  2,300 
Manufacturing expenses 499  244  1,598  1,042 
Selling, general and administrative expense 662  625  2,419  2,167 
Depreciation of tangible assets 199  182  589  536 
Total expenses 2,234  1,899  6,516  6,045 
Operating loss  (1,641)  (1,389)  (5,475)  (5,291) 
Finance and interest income  1  3  152  405 
Financing and interest expense (365)  (274)  (1,134)  (881) 
Net financing and interest income (expense) (364)  (271)  (982)  (476) 
Loss before income taxes (2,005)  (1,660)  (6,457)  (5,767) 
Deferred income tax  3  -  3  - 
Net loss (2,002)  (1,660)  (6,454)  (5,767) 
Other comprehensive (loss) income            
Foreign currency translation adjustment (175)  40  (518)  (108) 
Change in fair value 4  51  2  79 
  (171)  91  (516)  (29) 
Comprehensive loss$(2,173) $(1,569) $(6,970) $(5,796) 
Basic and diluted weighted average number of shares outstanding 150,590,729  110,259,652  131,576,774  107,818,057 
Basic and diluted loss per common share$(0.01) $(0.01) $(0.05) $(0.05)